Hsbc Holdings PLC Has $17.06 Million Holdings in Solventum Co. (NYSE:SOLV)

Hsbc Holdings PLC lowered its position in Solventum Co. (NYSE:SOLV - Free Report) by 37.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 258,216 shares of the company's stock after selling 157,644 shares during the period. Hsbc Holdings PLC owned 0.15% of Solventum worth $17,060,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. New York Life Investment Management LLC boosted its position in Solventum by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company's stock valued at $1,223,000 after acquiring an additional 136 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company's stock valued at $549,000 after purchasing an additional 161 shares during the period. Avantax Advisory Services Inc. boosted its position in shares of Solventum by 2.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company's stock valued at $584,000 after purchasing an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Solventum by 48.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock worth $45,000 after purchasing an additional 223 shares during the period. Finally, Savant Capital LLC increased its holdings in Solventum by 6.3% in the fourth quarter. Savant Capital LLC now owns 3,914 shares of the company's stock worth $259,000 after purchasing an additional 233 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. Wells Fargo & Company raised their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their price target on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Solventum currently has an average rating of "Hold" and a consensus target price of $79.86.

Solventum Price Performance

SOLV stock opened at $66.14 on Friday. The company has a market capitalization of $11.44 billion and a P/E ratio of 24.05. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The business has a 50-day simple moving average of $72.58 and a two-hundred day simple moving average of $71.58. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.